Patients with hidradenitis suppurativa experienced

In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve...

Related Keywords

Massachusetts ,United States ,Trinidad And Tobago ,Switzerland ,Trinidad ,America ,Acta Derm Venereol ,Clin Aesthet Dermatol ,Hidradenitis Suppurativa ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Richard Jarvis ,Novartis Cosentyx ,Isabella Zinck ,Michael Meo ,Dermatol Venereol ,Mac Mahon ,Satoshi Sugimoto ,Julie Masow ,Sloan Simpson ,Mary Carmichael ,Angelika Jahreis ,Alexab Kimball ,Clinical Development Excellence ,Twitter ,Beth Israel Deaconess Medical Center ,Professor Of Dermatology At Harvard Medical School ,Novartis ,Exchange Commission ,Novartis Europharm ,Novartis Pharmaceuticals Corp ,Global Head Development Unit Immunology ,Harvard Medical ,Hidradenitis Suppurativa Clinical Response ,Numeric Rating Scale ,Rev Dis ,Acta Derm ,Provides Sustained Improvements ,Psoriatic Arthritis ,Pooled Safety ,Its Effect ,Health Related Quality ,Patient Reported Outcomes ,Patient Relat Outcome ,Manuels D ,Antoniom L ,Skin Disease ,Related Quality ,Life Rijeka ,Swiss Stock Exchange Novn ,Novartis Pharma Ag ,Media Release ,Reimagine Medicine ,Innovation ,